Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
SK Channels as a New AAD Target
Author(s): Arnela Saljic , Jordi Heijman , Dobromir Dobrev Added: 5 months ago

Electrophysiology & Arrhythmia
Conduction System Pacing: A Fresh Look
Author(s): Óscar Cano , Marek Jastrzębski , Pugazhendhi Vijayaraman Start date: Nov 13, 2024
Conduction System Pacing: Recent Advances and Clinical ApplicationsConduction system pacing (CSP) has significantly evolved in recent years, expanding from His bundle pacing to include left bundle branch pacing and left ventricular septal pacing. This webinar, led by Dr Pugazhendhi Vijayaraman, a renowned expert in the field, features presentations from esteemed faculty, Prof Marek Jastrzębski… View more

Heart Failure

Electrophysiology & Arrhythmia
HRS 24: The BIO-CONDUCT Study
Author(s): Larry Chinitz Added: 1 year ago
HRS 24 - Dr Larry Chinitz (NYU School of Medicine, US) joins us to discuss the findings of the prospective, multicenter BIO-CONDUCT study, which investigated the safety and efficacy of the BIOTRONIK Solia S pacing lead implanted in the left bundle branch area (LBB) (NCT05251363, Biotronik Inc.). 186 patients with atrioventricular block, bradycardia, left bundle-branch block or cardiomyopathies… View more

Electrophysiology & Arrhythmia
EHRA 24: AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease
Author(s): Laurent Fiorina Added: 1 year ago
EHRA 24 - In this short interview, we are joined by Dr Laurent Fiorina (Cardiovascular Institute Paris-Sud (ICPS), FR) joins us to discuss the findings from a clinical investigation into diagnosing conduction tissue disease using an AI-enabled single-lead coronary ECG device.This observational, prospective clinical trial aims to investigate the performance of an artificial intelligence algorithm… View more

Imaging & Diagnostics

Electrophysiology & Arrhythmia
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 2 months ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
Calcium Modification Techniques for Coronary Artery Disease
Author(s): Rodrigo Bagur , Angela McInerney , Rolf Kreutz , et al Start date: Apr 23, 2025
This webinar brings together leading experts Dr Rodrigo Bagur, Dr Angela McInerney, Dr Rolf Kreutz, Dr Sohail Khan, Dr Sophia Khattak, Dr Jonathan Hinton and Dr Peter O’Kane to explore the challenges and solutions in managing calcified coronary artery disease. The session will provide a detailed examination of coronary calcification from pathological and clinical perspectives, including… View more

Intervention
Author(s): Alexander Fanaroff Added: 1 year ago
ACC.24 — Dr Alexander Fanaroff (Penn Medicine, US) joins us onsite at ACC.24 to discuss the findings from the BE ACTIVE study, which investigated behavioural economic approaches to increasing physical activity (PA) in patients with an elevated risk of cardiovascular disease (NCT03911141).This randomized, controlled trial enrolled 1062 patients with a 10-year atherosclerotic cardiovascular risk… View more

Prevention & Chronic Conditions
Levosimendan in Cardiogenic Shock
Author(s): Hendri Susilo , Fan Maitri Aldian , Citrawati Dyah Kencono Wungu , et al Added: 7 months ago

MI/ACS
ACC.24: Zilebesiran in Patients With Hypertension: KARDIA-2
Author(s): Akshay S Desai Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Akshay Desai (Brigham and Women's Hospital, US) to discuss the findings from the KARDIA-2 randomized clinical trial (NCT05103332).KARDIA-2 is a double-blind, placebo-controlled multicenter study aiming to evaluate the effects of zilebesiran, an RNA interference agent, on the systolic and diastolic blood pressure of hypertensive patients not… View more

Prevention & Chronic Conditions
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 6 days ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Renal Metabolic